


CLAIMS

1. A compound of formula (I)



wherein

R¹ is hydrogen or methyl,

and


R^{2A} and R^{2B} are independently selected from the group consisting of hydrogen, fluoro, chloro, cyano, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethyl, methoxy, difluoromethoxy and trifluoromethoxy,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.


2. The compound of formula (I) according to Claim 1, wherein
R¹ is hydrogen or methyl,
and
R^{2A} and R^{2B} are independently selected from the group consisting of hydrogen, fluoro, chloro, methyl and methoxy,
wherein at least one of R^{2A} and R^{2B} is other than hydrogen,
or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.
3. The compound of formula (I) according to Claim 1 or 2, wherein the compound is selected from the group consisting of
5-(4-chlorophenyl)-2-[(1-(3-chlorophenyl)-5-(hydroxymethyl)-1H-1,2,4-triazol-3-yl)-methyl]-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
5-(4-chlorophenyl)-2-[(1-(3-fluorophenyl)-5-(hydroxymethyl)-1H-1,2,4-triazol-3-yl)-methyl]-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
5-(4-chlorophenyl)-2-[(5-(hydroxymethyl)-1-(2-methylphenyl)-1H-1,2,4-triazol-3-yl)-methyl]-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
2-[(1-(2-chloro-4-fluorophenyl)-5-[(1RS)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
2-[(1-(2-chloro-4-fluorophenyl)-5-(1-hydroxyethyl)-1H-1,2,4-triazol-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (*diastereomer 1*);
2-[(1-(2-chloro-4-fluorophenyl)-5-(1-hydroxyethyl)-1H-1,2,4-triazol-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (*diastereomer 2*);
2-[(1-(2-chloro-5-fluorophenyl)-5-[(1RS)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
2-[(1-(2-chloro-5-fluorophenyl)-5-(1-hydroxyethyl)-1H-1,2,4-triazol-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (*diastereomer 1*);
2-[(1-(2-chloro-5-fluorophenyl)-5-(1-hydroxyethyl)-1H-1,2,4-triazol-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one (*diastereomer 2*);
5-(4-chlorophenyl)-2-[(1-(3-fluorophenyl)-5-[(1RS)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl)methyl]-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
5-(4-chlorophenyl)-2-[(1-(3-fluorophenyl)-5-[(1R)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl)-methyl]-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-(4-chlorophenyl)-2-({1-(3-fluorophenyl)-5-[(1*S*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1*RS*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1*R*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1*S*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(2-chlorophenyl)-5-[(1*RS*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(2-chlorophenyl)-5-[(1*R*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 and
 5-(4-chlorophenyl)-2-({1-(2-chlorophenyl)-5-[(1*S*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.


4. The compound of formula (I) according to Claim 1, 2 or 3, wherein the compound is selected from the group consisting of
 5-(4-chlorophenyl)-2-({1-(3-fluorophenyl)-5-[(1*RS*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(3-fluorophenyl)-5-[(1*S*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1*RS*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1*S*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 5-(4-chlorophenyl)-2-({1-(2-chlorophenyl)-5-[(1*RS*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one; and
 5-(4-chlorophenyl)-2-({1-(2-chlorophenyl)-5-[(1*S*)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl}-methyl)-4-[(2*S*)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one;
 or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.
5. Process for preparing a compound of formula (I) as defined in Claims 1 to 4, **characterized in that** a compound of formula (II)



is first reacted with hydrazine to give the hydrazide of formula (III)




then condensed with an amidine of formula (IV)



or a salt thereof,

wherein R¹ has the meaning indicated in Claim 1 to 4,


in the presence of a base to give a 1,2,4-triazole derivative of formula (V)



and/or a tautomer thereof,


wherein R¹ has the meaning indicated in Claim 1 to 4,

and subsequently coupled with a phenylboronic acid of formula (VI)



wherein R^{2A} and R^{2B} have the meanings indicated in Claim 1 to 4,


in the presence of a copper catalyst and an amine base to yield the target compound of formula (I)



wherein R^1 , R^{2A} and R^{2B} have the meanings indicated in Claim 1 to 4,

optionally followed, where appropriate, by (i) separating the compounds of formula (I) thus obtained into their respective diastereomers, and/or (ii) converting the compounds of formula (I) into their respective hydrates, solvates, salts and/or hydrates or solvates of the salts by treatment with the corresponding solvents and/or acids or bases.

6. Compound as defined in any of Claims 1 to 4 for use in the treatment and/or prevention of diseases.
7. Compound as defined in any of Claims 1 to 4 for use in a method for the treatment and/or prevention of acute and chronic heart failure, cardiorenal syndrome, hypervolemic and euvolemic hyponatremia, liver cirrhosis, ascites, edema and the syndrome of inadequate ADH secretion (SIADH).
8. Use of a compound as defined in any of Claims 1 to 4 for the manufacture of a pharmaceutical composition for the treatment and/or prevention of acute and chronic heart failure, cardiorenal syndrome, hypervolemic and euvolemic hyponatremia, liver cirrhosis, ascites, edema and the syndrome of inadequate ADH secretion (SIADH).
9. Pharmaceutical composition comprising a compound as defined in any of Claims 1 to 4 and one or more pharmaceutically acceptable excipients.
10. The pharmaceutical composition of Claim 9 further comprising one or more additional therapeutic agents selected from the group consisting of diuretics, angiotensin II antagonists, ACE inhibitors, beta-receptor blockers, mineralocorticoid receptor antagonists, organic nitrates, NO donors, activators of the soluble guanylate cyclase, stimulators of the soluble guanylate cyclase and positive-inotropic agents.
11. The pharmaceutical composition as defined in Claim 9 or 10 for the treatment and/or prevention of acute and chronic heart failure, cardiorenal syndrome, hypervolemic and euvolemic hyponatremia, liver cirrhosis, ascites, edema and the syndrome of inadequate ADH secretion (SIADH).
12. 5-(4-Chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl)methyl}-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H,2,4-triazol-3-one according to Claim 1 of the following formula



or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

13. The compound of claim 12, wherein the compound is 5-(4-Chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1*H*-1,2,4-triazol-3-yl)methyl}-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one of the following formula

